This document discusses Johnson & Johnson's acquisition of Alios BioPharma to strengthen its infectious diseases pipeline. Some key points: - J&J acquired Alios BioPharma, a clinical-stage biopharma company focused on viral diseases, for $1.75 billion in cash to bolster its existing infectious diseases therapeutic area. - Alios provides a nucleoside technology platform, a portfolio of lead compounds in early development, biotech-minded development operations, and key experts to J&J. - The goal is to fully integrate Alios and Janssen infectious diseases R&D teams across sites in San Francisco, Beerse, Shanghai, and Titusville-Raritan